Spur Therapeutics today announced that it will share updated clinical data from its Phase 1/2 GALILEO-1 and GALILEO-2 trials of avigbagene parvec (FLT201), its Phase 3 gene therapy candidate for Type ...

Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will ...

BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by ...

Charlie Smith. Poster exhibit. Case of Fetal Immature Trauma. The Southern Radiological Conference, Marriott's Grand Hotel, Resort and Spa, Point Clear, Alabama, January 25-27, 2013. Charlie Smith.

Company will provide an overview of the pritelivir clinical development program in two oral presentations including a comprehensive Phase 2 data overview Updated safety and pharmacokinetic results of ...

TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...

CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care, Inc. today announced that new data from studies evaluating the utility of the Zoom Stroke Solution for the treatment of ischemic stroke will be ...

Poster presentations are used to disseminate new knowledge at scientific conferences and meetings and to provide opportunities for liaison within the scientific community. The factors that influence ...

Two-year follow up of FLT201 AAV gene therapy in adults with Type 1 Gaucher Disease: Results from GALILEO-1 and GALILEO-2 Session: Clinical Applications Date & Time: Thursday, February 5, 9:30 a.m.